Arcadia Biosciences (RKDA)
(Delayed Data from NSDQ)
$2.09 USD
+0.19 (9.99%)
Updated Apr 26, 2024 03:49 PM ET
4-Sell of 5 4
D Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RKDA 2.09 +0.19(9.99%)
Will RKDA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RKDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RKDA
New Strong Sell Stocks for April 22nd
Arcadia Biosciences (RKDA) Q4 Earnings Beat Mark, Sales Up Y/Y
RKDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcadia Biosciences (RKDA) Reports Q4 Loss, Misses Revenue Estimates
Zacks Industry Outlook Highlights like West Fraser Timber, CalMaine Foods, GrowGeneration, Hydrofarm and Arcadia Biosciences
5 Agriculture - Products Stocks to Watch in a Challenging Industry
Other News for RKDA
Arcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference Call
SNDL, Arcadia Biosciences among Consumer Staples movers
Warning: RKDA is at high risk of performing badly
Buy Rating on Arcadia Biosciences Fueled by Strategic Initiatives and Innovative Product Launches
Buy Rating Affirmed for Arcadia Biosciences Amidst Growth and Strategic Shifts